drug · small molecule
olanzapine ER
pre_registrationupdated 3mo agoby $TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval872 co-mentions · 299 sources
- drugLYBALVI718 co-mentions · 300 sources
- drugOLANZAPINE711 co-mentions · 300 sources
- drugolanzapine ODT437 co-mentions · 300 sources
- tagSmall Molecule318 co-mentions · 239 sources
- drugOLANZAPINE AND FLUOXETINE HYDROCHLORIDE180 co-mentions · 60 sources
- drugFLUOXETINE HYDROCHLORIDE120 co-mentions · 60 sources
- drugolanzapine pamoate XR120 co-mentions · 30 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 27 investigational indications.
targets
D2-like dopamine receptor5-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 2A
all catalysts(0)
nothing on the calendar yet
Trials studying olanzapine ER
- phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
- phase3Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- phase1Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
- phase1An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
- —A Study of Olanzapine in Participants With Bipolar Disorder.
- phase1Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
- phase1Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
- phase3A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
News(1)
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 11d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that